Individualization of attention-deficit/hyperactivity disorder treatment: pharmacotherapy considerations by age and co-occurring conditions.

This article combines current information from the literature and the first-hand experience of the authors to provide guidance on ADHD treatment options for patients of different ages and for some of the more common comorbidities. PMID: 32054558 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/32054558?dopt=Abstract

Source: CNS Spectrums - February 13, 2020 Category: Neurology Authors: Mattingly GW, Wilson J, Ugarte L, Glaser P Tags: CNS Spectr Source Type: research

More News: ADHD | Brain | Food and Drug Administration (FDA) | Hyperactivity | Neurology